Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixteen patients (median age 67 yrs.) with non-Hodgkin lymphoma of the testis were studied. Twelve of these patients had disease that was classified as local (Stages IE and IIE). Eight patients had diffuse histiocytic lymphoma, 6 had diffuse poorly differentiated lymphocytic lymphoma, 1 had both lymphoma and seminoma, and 1 had nodular poorly differentiated lymphocytic lymphoma. The overall median survival was 9.5 months. Para-aortic nodal involvement was the factor that had the strongest prognostic influence with the management methods used. Median survival without para-aortic nodal involvement was 57+ months, but with such involvement it was 6 months (p = 0.002). There is a high probability of generalized disease if lymphoma can be detected in the para-aortic nodes. For patients with Stages IE and IIE disease, radical radiation therapy is the preferred treatment. For those with disseminated disease, chemotherapy, with irradiation reserved for symptomatic and bulky localized deposits, is the recommended method of management.
 ...
PMID:Non-Hodgkin lymphoma of the testis. 705 33

The finding of general symptoms in Hodgkin's disease is accepted as bad prognostic sign and expression of disease activity. Results of clinical and histological classification analysis indicate the possibility of different interpretation of the presence and absence of symptoms in generalized disease. Asymptomatic generalized disease can be prognostically more serious than that of symptomatic one as it may express immunological tolerance of the tumor or acquired depression of defensive mechanisms. This conclusion is supported by preliminary data on survival of our patients in given classification groups.
 ...
PMID:Interpretation of clinical symptoms in Hodgkin's disease. 726 7

Hodgkin's disease has become the prototype of a curable neoplastic condition. In localized disease (stages I and II) cure can be achieved with radiotherapy alone unless B-symptoms are present. In case of B-symptoms or generalized disease (stages III and IV) the administration of polychemotherapy is mandatory. In advanced stages combinations of the non-cross-resistant regimens MOPP and ABVD seem to be the most effective. In patients relapsing from the MOPP/ABVD or MOPP/ABV regimen salvage chemotherapy offers a chance of remission but not cure. Such patients, in particular those with a short first remission, are candidates for autologous stem cell transplantation which can still induce durable remissions in a subset of patients. Considering the long term complications such as infertility and the development of secondary neoplasms one has to carefully balance the benefits against the potential risks of the initial treatment approach.
 ...
PMID:[Therapy of Hodgkin's disease]. 805 98

In 1992, after a history of more than two decades a subgroup within the diffuse low-grade B cell lymphomas designated centrocytic lymphoma, lymphocytic lymphoma of intermediate differentiation or mantle zone lymphoma gained general acceptance, now referred to as mantle cell lymphoma. Similarities between these entities were emphasized by identification of rearrangement and overexpression of CCND1 (bcl1/PRAD1) gene in the majority of cases. Unlike in all other non-Hodgkin's lymphomas sex distribution demonstrates a striking preponderance of males over females with a ratio of 3:1. Initial parameters in all published series are advanced disease with generalized lymphadenopathy in 90%, bone marrow infiltration in 60-75%, splenomegaly in 55%, hepatomegaly in 35%, gastrointestinal involvement in about 25% and peripheral blood lymphocytosis in 20-30% of patients. In generalized disease, clinical course is characterized by continuous progression with a median survival probability of 3-4 years within most series. Overall response rates of 56-88% with complete remissions in the range of 9-58% are attainable but relapse occurs predominantly within 20 months. At present there is no evidence that any conventional regimen is curative. Prospective multicenter studies are mandatory to overcome this therapeutic dilemma. Patients suitable for some form of maintenance or consolidation therapy should initially be treated intensively by anthracycline-containing regimens. Whether maintenance with interferon or intermittent chemotherapy including new agents, like purine analogues or (un)conjugated monoclonal antibodies are able to influence overall survival is a matter of (ongoing) investigations. Further experimental approaches arise from antisense oligonucleotides or ribozymes blocking the overexpression of bcl-1 especially in this lymphoma entity. At present high-dose myeloablative consolidation radiochemotherapy followed by stem cell rescue in first remission seems to be the most attractive option in younger patients.
 ...
PMID:Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. 917 43

Mantle-cell lymphoma comprises 2%-10% of all non-Hodgkin's lymphomas (NHLs). Patients present with generalized disease, and have a poor prognosis. Three different histologic patterns (mantle zone, nodular, and diffuse) and three different cytological variants (classical, blastic, and pleomorphic) have been described. The phenotype (strong surface IgM, CD5+, CD10-, CD23-, cyclin D1+ and B-cell markers+) is remarkably constant. Dependent on the methods used (PCR, Southern blot analysis, and cytogenetics) a t(11;14) can be detected in approximately 35%-66% of cases. Using FISH analysis, possibly almost all cyclin D1-expressing MCLs carry this translocation, indicating that a substantial part of these translocations are missed by conventional methods. This has been confirmed by DNA fiber FISH analysis by which the breakpoints could be accurately mapped over a 220 kb region centromeric of the cyclin D1 gene. Additional genetic abnormalities involve breakpoints and deletion at the 3' end of the cyclin D1 gene, numerical chromosomal aberrations, mutations in p53, and deletions of p16. These may be associated with tumor progression. Owing to the translocation t(11;14), the cyclin D1 gene is activated. At the RNA level, approximately 90% of MCLs show overexpression. This corroborates immunohistochemistry on paraffin tissue sections. Since expression of cyclin D1 in normal lymphoid cells is very low to undetectable, and only hairy-cell leukemia and very few other B-cell lymphomas show expression, immunohistochemistry for cyclin D1 provides an excellent marker for MCL. In hairy-cell leukemia, expression is moderate and cannot be explained by chromosomal translocation.
 ...
PMID:Bcl-1/cyclin D1 in malignant lymphoma. 920 53

In the palliative treatment of advanced SCLC and NSCLC there is a big need for effective and well tolerable drugs. Bendamustin is an alcylatic agent which had shown activity in the treatment of Non Hodgkin- and Hodgkin-Lymphoma as well as in the treatment of solid tumors like Mamma-Carcinoma and Colorectal-Carcinoma. We treated 21 patients with NSCLC (5 pat. Stad. III b, 16 pat. Stad. IV) and 22 pat. with Extensive Disease SCLC with Bendamustin 70 mg/m2 i.v., day 1-4 (q.28 days). We observed a response rate of 40.9% in the patients with SCLC (9 PR/40.9%), (0 CR) and no response in the patients with NSCLC. Hematologic toxicity in both groups was mild (Leucopenia WHO 1 + 2: 13 pat./30.2%, WHO 3: 2 pat./4.6%; Anemia WHO 1 + 2: 13 pat./30.2%, WHO 3: 1 pat./2.4%; Thrombopenia WHO 1 + 2: 4 pat./9.6%, WHO 3: 1/2.4%). Non Hematologic toxicity consisting of Nausea/Vomiting (WHO 2 + 3:13 pat./30.2%), Diarrhea (WHO 2 + 3:3 pat./7%), Obstipation (WHO 1 + 2: 2 pat./4.6%), Fever (WHO 1 + 2: 9 pat./20.9%) and Alopecia (WHO 1 + 2: 13 pat./31.7%, WHO 3: 1 pat./2.4%) was well tolerable. Cardiac Arrhythmias occurred in 7 pat./16.3% and PNP in 2 pat./4.6%. Treatment had to be stopped in one patient because of an allergic skin reaction. Bendamustin is a well tolerable cytostatic drug with a remarkable activity in advanced SCLC which is comparable to other well known agents in the treatment of this disease. Because of the good toxicity profile a combination with other compounds might be feasible. In advanced NSCLC Bendamustin showed no activity.
 ...
PMID:[Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]. 984 35

The Authors have carried out a retrospective study on 353 cases of lymphoma, of which 252 of non-Hodgkin lymphoma (NHL) and 101 cases of Hodgkin's disease (HD), during a 17 year period, i.e. from 1982 to 1999, with the purpose of evaluating the frequency of primitive and secondary extra-nodal localizations and assess their influence on the percentage of survival. A highly significant statistical difference was observed comparing patients with nodal LNH and those with a primitive extra-nodal localization of the disease. In HD extra-nodal localizations were observed at the time of diagnosis in 13% of the cases studied, in which however in the great majority of patients presentation was associated with generalized disease and was therefore the consequence of local spread from near-by lymphoid sites. However, primitive localizations were surely observed and carefully documented. In our patients they were detected in the intestine, in the skin and in the mammary gland. In 253 patients with NHL, 123 sites of extranodal localizations were found (50%) and were observed in the skeletal system, in the skin and in the orbital cavity. The Authors underline the need to improve our knowledge on the structures and mechanisms of spread of the mucosal associated lymphoid tissue in order to better understand the clinical aspects and the necessary therapeutic approach in cases of extranodal and especially MALT lymphomas.
 ...
PMID:[Extranodal localizations of lymphoma. Clinico-epidemiologic study of 353 cases]. 1107 37

The clinical observations of 207 patients with non-Hodgkin's lymphomas, treated with radiotherapy and chemoradiotherapy at our institution in 1999-2012 years, were presented. 136 patients had the extranodal lymphomas, 40 patients had plasma cell tumors and 31 patients had follicular lymphoma. Complete regression of the lesions was observed in all 24 patients with a local lesion of the skin, an objective response of a variable degree was received in all 27 patients with generalized disease within skin. The radiation therapy of the stomach and perigastric lymph nodes led to complete remission in 100% cases. Conformal radiotherapy with 3D-planning in patients with a primary lesion of the orbit avoided irradiation of the intact eye. The 3 Gy fractionation mode was more effective in the treatment of myeloma and solitary plasmacytoma of bone, whereas the standard fractionation mode was more effective in patients with extraosseous plasmacytoma. Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields.
 ...
PMID:[Current technologies in radiotherapy for non-Hodgkin lymphomas]. 2403 29

Primary lymphoma of the lung or pleural is a very rare condition. Due to the outdated literature data, the approximate occurrence of primary and secondary lung and/or pleural involvement according to the most common B cell lymphoma entities is unknown. To answer this open question in Austria, we screened the Tyrolean registry for B cell non-Hodgkin's lymphomas regarding primary and secondary lung involvement. Of 854 patients affected by B cell lymphoma, 7.5% had lung/pleural disease. This organ was the primary site in only 0.7%, while a secondary involvement was registered in 6.8%. Most of them were affected by diffuse large B cell lymphoma (DLBCL; 29/368, 8%) followed by follicular lymphoma (7/188, 4%), mantle cell lymphoma (7/57, 12%), mucosa-associated tissue lymphoma (10/37, 27%), posttransplant lymphoproliferative disease (6/24, 25%), Burkitt lymphoma (3/19, 16%), other lymphomas (1/32, 3%) and Richter transformation (1/11, 9%). Moreover, primary lung/pleural lymphoma is one of the rarest neoplasias affecting the lung, accounting for only 0.4% of cases. Lung/pleural involvement is a very rare condition among B cell lymphomas since it mainly occurs in the setting of a generalized disease. A large majority of patients with secondary organ involvement are affected by DLBCL and have similar clinical features at diagnosis to others with advanced-stage disease.
 ...
PMID:B cell lymphoma with lung involvement: what is it about? 2537 8


<< Previous 1 2